Selective kinetic spectrophotometric method for determination of gatifloxacin based on formation of its N-vinyl chlorobenzoquinone derivative

The use of complex formation manner for spectrophotometric analysis of gatifloxacin drug based on Co(II), Ni(II) and La(III) ions

Herein, a simple and accurate spectrophotometric method was developed to detect gatifloxacin (HGAT) in a pure and ophthalmic formulation. The method depends on complexation of HGAT with Co (II), Ni (II) and La(III) ions in ethanol medium at room temperature. The experimental conditions have been investigated to reach optimum conditions for HGAT-metal ions interaction, including detection of a suitable wavelength, medium pH, reaction time and reactants concentration. Moreover, the composition of these complexes in addition to their stability constants were also investigated and the result indicated that the molar ratio of HGAT: Metal ion is 1:1 for Ni (II) and La(III) ions and 1:2 for Co (II) ion. Beer's law plots were obeyed in the concentration ranges 18.77-150.16, 18.77-131.39 and 18.77-112.62 (μg mL-1) for Co(II), Ni(II) and La(III) ions interaction, respectively. The apparent molar absorptivity, Sandell's sensitivity, standard deviation, detection and quantification limits were calculated. The proposed method was successfully applied for the determination of HGAT in the bulk and ophthalmic formulation. The obtained results were compared statistically with other published methods and the results were in good agreement with those obtained by reported methods.

New Derivatization Methodology of 4-aminobenzoic Acid from its Dietary Supplements: Kinetic Spectrophotometric Methods for Determination

Background:

A new approach describing the validation and development of an easy, new spectrophotometric and kinetic method for identification of para-aminobenzoic acid in dietary supplement has been performed. In this study, para-aminobenzoic acid was derived in a pH-controlled environment, as a new organic compound 4(4-Benzophenylazo)pyrogallol, by incorporating diazotized para-aminobenzoic acid with pyrogallol.

Objective:

The determination of para-aminobenzoic acid was conducted by the fixed time and initial rate techniques. These approaches were based on the reaction of the compound containing paraaminobenzoic acid, 4(4-Benzophenylazo)pyrogallol, with Ag(I) to form colored product with a maximum absorbance at 468nm. Both of these techniques were adopted for constructing the calibration curves and examined for their suitability for the quantitation of para-aminobenzoic acid in dietary supplement.

Methods:

The determination process was established, using initial rate and fixed time kinetic spectrophotometric methods.

Results:

4(4-Benzophenylazo)pyrogallol was characterized using proton-nuclear magnetic resonance, Fourier-transform infrared, differential scanning calorimetry and thermogravimetric thermal methods, gas chromatography–mass techniques, and solvatochromic behavior in solvents with different polarities was also examined.

Conclusion:

For the first time, para-aminobenzoic acid was well determined by incorporating it as an organic solid compound, 4(4-Benzophenylazo)pyrogallol, through coupling pyrogallol with diazotized para-aminobenzoic acid in regulated pH medium, ranging between 5.0 to 6.0. The existence of common excipients in the dietary supplement did not produce any significant interference. F- and ttest data analysis were used for statistical comparison of the suggested techniques with that of reference method, demonstrating excellent agreement with no significant difference in the associated precision and accuracy.

The influence of pH on the stability of antazoline: kinetic analysis

Degradation of the drug antazoline was studied in aqueous solutions by means of pH-rate profiling (pH 0–7.4).

Ultrasensitive study of gatifloxacin based on its enhancing effect on the cerium (IV)-sodium hyposulfite chemiluminescence reaction in a micellar medium

A sensitive and rapid flow-injection chemiluminescence (CL) method has been developed for the determination of gatifloxacin in pharmaceutical preparations and biological samples. The method is based on the enhancing effect of gatifloxacin on CL emission generated by the interaction of Ce (IV) in sulphuric acid and sodium hyposulphite (Na(2)S(2)O(4)) sensitized by sodium dodecyl benzene sulfonate (SDBS). Strong CL emission was observed when gatifloxacin was injected into the Ce (IV) in sulphuric acid and Na(2)S(2)O(4) solution incorporated with SDBS in a flow-cell. Several experimental parameters affecting the CL reaction were investigated and optimized systematically. Under the optimum conditions, it was found that the CL intensity is proportional to the concentration of gatifloxacin in the range of 1.12 × 10(-11)-4.40 × 10(-9) g mL(-1) with a co-relation coefficient of 0.9994. The limit of detection was found to be 4.87 × 10(-12) g mL(-1) and the relative standard deviation (RSD, n=7) was 1.8% for 4 × 10(-8) g mL(-1) of GFLX. The proposed method offers higher sensitivity, wide linear range and better stability without requiring sophisticated instrumentation. Thus, the proposed method has been successfully applied to the determination of gatifloxacin in pharmaceuticals, serum and human urine.